Actuarial disease-free survival from remission for patients with (A) or without (B) activating mutations on the basis of postinduction therapy. Patients with matched family donor received an allogeneic bone marrow transplant (allogeneic BMT). Those without a family donor received either autologous BMT or chemotherapy (no allogeneic BMT). *P reflects log-rank comparison.